Celcuity's FDA Approval of Revtopik Faces Challenges with High Launch Costs
On July 14, Celcuity (NASDAQ:CELC) received FDA approval for its breast cancer drug Revtopik. The company is transitioning from a clinical-stage biotech to one launching its first commercial product. Despite strong trial data showing improved progression-free survival and fewer side effects compared to existing treatments, the financial burden of scaling up operations has increased significantly. Celcuity reported a net loss widening to $78.9 million for Q2 2026 due in part to rising SG&A expenses from building its commercial team ahead of product shipments expected later this quarter. The company also announced plans to expand trials into treatment-naive patients, supported by promising early data. Despite these developments, investor confidence appears mixed; hedge fund ownership slightly declined during the last reporting period.
Tickers: $CELC